May 18, 2004

Conservative treatment in noninvasive breast cancer

Nuria RodríguezFerran Ferrer


The elective treatment for noninvasive breast carcinoma has not yet been established. As a result of mammographic screening programs, the incidence of noninvasive tumors has increased and has lead to the same controversy already present had with invasive carcinomas: mastectomy or conserving therapy. Since 1990, 101 patients with noninvasive breast cancer were treated with irradiation following breast-conserving surgery. All the patients had irradiation of the whole breast (mean dose, 47.6 +/- 1.2 Gy). The radiation dose boost to the tumor bed was delivered in 28.7% of the cases (mean dose, 21.03 +/- 3.06 Gy), and in 71.3%, the boost was not administered. With a median follow-up of 34 months, survival is 100%. The disease-free survival at 5 years by the Kaplan-Meier method is 93.6 +/- 8.65. The conserving treatment is a valid option for treatment of patients with ductal carcinoma in situ.

  • References
  • Citations


  • We're still populating references for this paper, please check back later.
  • References
  • Citations


  • This paper may not have been cited yet.

Mentioned in this Paper

Noninfiltrating Intraductal Carcinoma
Ductal Carcinoma
Survival Analysis
Breast-Conserving Surgery
Radiotherapy, Adjuvant
Mammary Neoplasms, Human
Breast Carcinoma
Malignant Neoplasm of Breast

About this Paper

Related Feeds

Carcinoma, Ductal

Ductal carcinoma is a malignant neoplasm involving the ductal systems of any of a number of organs, such as the mammary glands, pancreas, prostate or lacrimal gland. Discover the latest research on ductal carcinoma here.

Related Papers

Journal of the Medical Association of Thailand = Chotmaihet Thangphaet
Saipin Tangkaratt
Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft ... [et al]
M DeutingerE Biber
The Breast : Official Journal of the European Society of Mastology
Shunsuke OnoeHitoshi Tsuda
Archives of Gynecology and Obstetrics
Jing HanPeter Hillemanns
© 2020 Meta ULC. All rights reserved